From test tube to drug delivery – joint research by AstraZeneca and Glasgow

The University of Glasgow is working with global pharmaceutical company AstraZeneca to speed up the development of new medicines based on fundamental breakthroughs in science. The goal of the three-year collaboration is to identify new pathways by which inflammation can promote diseases and ultimately create better medicines for patients.

The partnership sees one of AstraZeneca’s own research teams join forces with the Institute of Infection, Immunity and Inflammation at the University of Glasgow. The research team will be fully embedded within the University as the ‘GLAZgo Discovery Centre’. The company’s investment will help support 10 full-time staff and PhD students and enable secondments between the two organisations.

The partnership draws upon Glasgow’s excellence in understanding disease pathology and immunology and combines this with the drug discovery and development expertise of AstraZeneca. By integrating the research teams the partners aim to create an innovative and collaborative atmosphere which will help achieve scientific leadership, develop new drug programmes, and inform existing AstraZeneca programmes.

Related case studies

Reducing blood transfusions to lower patient risk, reduce costs and save lives

More than half a million people in the UK receive a blood transfusion each year and demand is increasing. Our ageing population, and a stringent donor selection process, mean the supply of blood is limited. 40% fewer new donors came forward last year compared with a decade ago. Recognising these challenges, researchers at the University of Edinburgh have shown the benefits of reducing the use of blood transfusions in intensive care and surgery.

Read more >